Navigation Links
GenoLogics Announces Bioinformatics Partnership with Illumina

GenoLogics Announces Bioinformatics Partnership with Illumina

BEYOND GENOME CONFERENCE, San Francisco, CA, June 21, 2007 -GenoLogics, a leading developer of lab and data management software solutions for life sciences research, today announced that it has penned an agreement with Illumina, Inc. to become a technology partner and participant in IlluminaConnect, a bioinformatics software program established by Illumina to advance data integration and analysis among the life science community.

GenoLogics will build integrations into Geneus that support Illumina?s BeadArray technology platforms and software for both gene expression and genotyping applications. Geneus includes science-specific modules that are purposed for multiple genomics application areas, and is built on an enterprise laboratory information management system (LIMS) platform designed for scientific lab and data management.

Omoshile Clement, Ph.D., Senior Product Manager, Platforms at Illumina commented, "We are very happy to welcome GenoLogics as a new IlluminaConnect partner, and we look forward to working with them to develop integrations to our technology platforms for genotyping and gene expression applications."

?I am very excited about our partnership with Illumina. We are looking forward to offering Geneus with integrations to their BeadArray analysis software, BeadStudio, which will enable our customers with gene expression and genotyping applications to tie their data together using one integrating LIMS system. We will work closely with Illumina to ensure we develop seamless integrations that provide end-to-end solutions for researchers using Illumina genomics software and technologies,? said Jason Wilson, Product Manager at GenoLogics.

The most significant benefit from this partnership for customers ?this integration to Illumina software will enable customers to interconnect the Illumina technologies i n their lab with a LIMS and data management system developed specifically to address gene expression and genotyping workflows and genomics applications. This will allow for smooth data flow from one system to another with an integrating LIMS system that acts as the informatics backbone in one or multiple labs.

GenoLogics CEO, Michael Ball adds, "Our partnership with Illumina extends our network of strategic partners, building on one of our core differentiators. Our strong ties with best-in-class vendors enable us to provide end-to-end solutions for applications such as translational medicine and systems biology."

GenoLogics' Geneus provides LIMS functionality specifically for gene expression and genotyping applications and integrates to a wide variety of genomics instruments and software from best-in-class vendors, such as Illumina.

About GenoLogics

GenoLogics is the leading provider of bioinformatics software solutions that help life science laboratories specializing in the field of proteomics, genomics, and systems biology research to manage, integrate, and analyze enormous volumes of scientific and lab data. The Company's mission is to catalyze life sciences research with a collaborative data management software platform, advancing the early detection, prevention, and treatment of disease. For more information, please visit www.genologics.com.

About Illumina

Illumina, Inc. (NASDAQ: ILMN) is a leading developer, manufacturer, and marketer of next-generation life science tools and integrated systems for the large-scale analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutic al companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients. For more information, please visit www.Illumina.com.

###

Contact info:

GenoLogics Life Sciences Software, Inc. Tanis MacSween Manager, Marketing Communications 250.483.7063 tanis.macsween@genologics.com

Maurissa Bornstein, Public Relations Manager Illumina, Inc. Ph: 858.332.5055 Email: mbornstein@illumina.com


'"/>




Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):